JAMA Dermatology

And so I actually think AI can facilitate getting patients to the right place.

You know, there's some JAMA Derm this last year published a really large cohort study showing that APPs in dermatology are providing the bulk of the care and are writing the bulk of the biologics in dermatology.

And so if you're a rheumatologist and you're not too keen on nurse practitioners and physician associates, You got to change that because they're important and they're really good by the way.

I mean, if you haven't dealt with them, I think that you, you should be looking forward to dealing with them going forward.

So let's have a look at the research to start with.

So there was a very small study published in JAMA Dermatology.

So that's one of the big journals.

And they found that improved cheek fullness after a 20-week facial exercise programme... did actually create a small difference so more of a little bit of a facial lift definitely not correcting hooded eyelids and what was interesting is that several women didn't complete it so it shows it's quite a tough thing to do and there was no comparison group so and this actually involved around half an hour of daily exercises initially and then every other day I don't know about you, but I do not have half an hour to exercise my face, especially if the benefits are not that great.

All right.

So the paper I picked for this week was in JAMA Dermatology, High-Dose Oral Vitamin D for Toxic Effects of the Skin Associated with Chemotherapy and Radiation.

So what is this? This is really high-dose vitamin D for toxic erythema of chemotherapy and a little bit on acute radiation dermatitis.

So, you know, I thought this isn't something that we all see every day, but these patients can be complicated.

Low-dose oral minoxidil, LDOM, has been used off-label in adults for years, but pediatric dermatologists have been flying blind on dosing and monitoring.

This is an international consensus statement published in JAMA Dermatology in September 2026.

And it gives a clear framework.

Starting microdoses of 0.25 to 0.625 milligrams daily based on age and body weight with slow step titration.

We're still trying to figure it out." We always wanna replete what, what we think is missing, but maybe focusing on those whole foods is really the ultimate and most important way to approach these disease states and really just healthy living in general.

All right, so now we're moving on to our third article, and this should be the big attention grabber because this was a, a wonderful publication in, uh, JAMA Dermatology back in twenty eighteen.

This was by Navarro Lopez and colleagues, and it was a randomized trial.

The title is Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index, and it also addresses topical steroid use in children with moderate AD.

Not sure if you have seen this, but I came across this article in JAMA..." Oh, my p- my page isn't open for it.

J- JAMA Derm, showing that HPV vaccine can treat pre-cancerous actinic keratoses.

And then there's a link that I haven't looked at.

Uh, and the title is "Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VACC-AK Randomized Clinical Trial." And so, uh, the main outcomes...

It's called clascoterone that blocks androgen receptors right in the skin without going through your entire his- system.

It's been through two large phase III trials published in JAMA Dermatology showing treatment success in 18% to 20% of patients compared to 6% to 9% on the inactive vehicle, which I'm not sure what their control was, and it makes it sound like it's a fairly reasonable safety profile to consider, so especially for women who don't wanna be on oral medication.

So that is the acne portion.

The other question that I got was from Nikki mentioning, "I'm 30.

Finally, we'll turn to differences in atopic dermatitis, comorbidity, and treatment patterns by race.

We'll start with our first article published in JAMA Derm entitled Melanoma Prevention Among Children of Melanoma Survivors, a randomized clinical trial by Yelena P. Rue, Tammy K. Stump, and Pascal R. Deboit, ADOL.

Children of melanoma survivors have approximately twice the lifetime melanoma risk of the general population, yet many remain inconsistently protected from UV exposure.

This randomized clinical trial assigned 364 melanoma survivor child dyads to the four-week Family, Lifestyles, Actions, and Risk Education, FLARE, Telehealth Intervention, or an Active Telehealth Education Control and Evaluated Sunburn, Sun Protective Behaviors, and Tanning.